scholarly journals Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions

2019 ◽  
Vol 26 (7) ◽  
pp. 953-960 ◽  
Author(s):  
J. J. Ferreira ◽  
A. Lees ◽  
J.‐F. Rocha ◽  
W. Poewe ◽  
O. Rascol ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Pooled Analysis ◽  
Open Label ◽  
Phase 3 ◽  
Two Phase ◽  
Term Efficacy

scholarly journals Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease

2019 ◽  
Vol 126 (3) ◽  
pp. 299-308 ◽  
Author(s):  
Nobutaka Hattori ◽  
Atsushi Takeda ◽  
Shinichi Takeda ◽  
Akira Nishimura ◽  
Tadayuki Kitagawa ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Japanese Patients ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Early Parkinson’S Disease

An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris

2019 ◽  
Vol 3 ◽  
pp. S1 ◽  
Author(s):  
Linda Stein Gold ◽  
Sunhil Dhawan ◽  
Jonathan Weiss ◽  
Zoe Diana Draelos ◽  
Herman Ellman ◽  
...  
Keyword(s):  
Acne Vulgaris ◽  
Open Label ◽  
Phase 3 ◽  
Two Phase ◽  
Term Efficacy ◽  
Open Label Extension

Abstract not available.

Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies

2019 ◽  
Vol 3 ◽  
pp. S25
Author(s):  
Benjamin Ehst ◽  
George Han ◽  
Scott Guenthner ◽  
Kimberly Eads ◽  
Abby Jacobson
Keyword(s):  
Disease Duration ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Two Phase ◽  
Term Efficacy

Abstract not available.

Risperidone in levodopa-induced psychosis in advanced parkinson's disease: An open-label, long-term study

1997 ◽  
Vol 12 (4) ◽  
pp. 610-612 ◽  
Author(s):  
Giuseppe Meco ◽  
Andrea Alessandri ◽  
Patrizia Giustini ◽  
Vincenzo Bonifati
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Open Label ◽  
Term Study ◽  
Advanced Parkinson’S Disease ◽  
Long Term Study

scholarly journals Update on Dopamine Agonists in Parkinson's Disease: “Beyond Bromocriptine”

1987 ◽  
Vol 14 (S3) ◽  
pp. 474-482 ◽  
Author(s):  
Anthony E. Lang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Dopamine Agonists ◽  
Infusion Therapy ◽  
Foreseeable Future ◽  
Phase 3 ◽  
Beneficial Effects ◽  
Elderly Humans ◽  
Ergot Derivative

ABSTRACT:Since the initiation of bromocriptine therapy for Parkinson's disease several newer dopamine agonists have been developed. Pergolide has reached the stage of Phase 3 clinical trials and will probably be available for general use sometime in the foreseeable future. Lisuride shows most promise in its parenteral form for infusion therapy of patients with severe fluctuations. Mesulergine, another ergot-derivative and ciladopa, a new non-ergot agonist, have been withdrawn from further clinical use due to tumorogenesis in rats. It is questionable how applicable these findings are to the use of the drugs in elderly humans with parkinsonism. Recently a small number of drugs have been found to have postsynaptic dopamine agonist properties only in the setting of denervated supersensitive dopamine receptors. These agents may be particularly effective in the early treatment of patients with Parkinson's disease. This paper will review a number of the dopamine agonists which have been developed since the introduction of bromocriptine therapy. Several of these have shown beneficial effects in early clinical trials while others show promise in preclinical studies of animal models of parkinsonism.

Sign in / Sign up

Export Citation Format

Share Document